Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Net Cash Flow (2016 - 2025)

Dexcom (DXCM) has disclosed Net Cash Flow for 16 consecutive years, with -$921.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 23530.77% to -$921.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $290.3 million, a 515.04% increase, with the full-year FY2025 number at $290.3 million, up 515.04% from a year prior.
  • Net Cash Flow was -$921.6 million for Q4 2025 at Dexcom, down from $677.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $677.7 million in Q3 2025 to a low of -$921.6 million in Q4 2025.
  • A 5-year average of $4.6 million and a median of -$12.0 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 2331.78% in 2023, then crashed 23530.77% in 2025.
  • Dexcom's Net Cash Flow stood at -$391.1 million in 2021, then surged by 83.99% to -$62.6 million in 2022, then tumbled by 33.23% to -$83.4 million in 2023, then skyrocketed by 95.32% to -$3.9 million in 2024, then plummeted by 23530.77% to -$921.6 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Net Cash Flow are -$921.6 million (Q4 2025), $677.7 million (Q3 2025), and $237.7 million (Q2 2025).